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While chimeric antigen receptor (CAR) T cells targeting CD19 can cure a subset of patients
with B cell malignancies, most patients treated will not achieve durable remission. Identiﬁcation of the mechanisms leading to failure is essential to broadening the efﬁcacy of this
promising platform. Several studies have demonstrated that disruption of CD19 genes and
transcripts can lead to disease relapse after initial response; however, few other tumorintrinsic drivers of CAR T cell failure have been reported. Here we identify expression of the
Golgi-resident intramembrane protease Signal peptide peptidase-like 3 (SPPL3) in malignant
B cells as a potent regulator of resistance to CAR therapy. Loss of SPPL3 results in hyperglycosylation of CD19, an alteration that directly inhibits CAR T cell effector function and
suppresses anti-tumor cytotoxicity. Alternatively, over-expression of SPPL3 drives loss of
CD19 protein, also enabling resistance. In this pre-clinical model these ﬁndings identify posttranslational modiﬁcation of CD19 as a mechanism of antigen escape from CAR T cell
therapy.
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cells engineered with chimeric antigen receptors (CARs)
targeting the transmembrane protein CD19 have varied
success in the treatment of B cell cancers. Response rates in
pediatric patients with acute lymphoblastic leukemia (ALL) are
high, with >85% achieving complete remission within 1 month of
treatment1,2. Unfortunately, many patients with ALL who achieve
remission ultimately relapse. Outcomes for patients with nonHodgkin lymphoma or chronic lymphocytic leukemia (CLL) are
more modest, with overall response rates of 30–50%3–8. These
clinical data demonstrate that while curative for some, most
patients treated with CAR T cells will not achieve long-term
remission.
Failure of CAR T cells can result from tumor-intrinsic
mechanisms, T cell-intrinsic mechanisms, or a combination of
both. Several studies have identiﬁed T cell-intrinsic features that
correlate with therapeutic failure, primarily related to memory
differentiation status or expression of exhaustion-associated
genes9–12. We previously reported that defects in cancer cell
apoptotic signaling enable resistance to CAR T cell cytotoxicity
that then drives the development of T cell dysfunction, implicating both cell types in disease progression13. Other studies have
identiﬁed mechanisms by which modulation of CD19 surface
expression can lead to resistance and relapse14. This process,
broadly referred to as antigen escape, manifests as an apparent
loss of surface CD19 expression by leukemic cells, making CAR
T cells “blind” to their presence and permitting disease outgrowth. Antigen escape can occur at the genetic level via loss of
entire CD19 alleles, resulting in failed protein expression, or loss
of partial genes, resulting in expression of a truncated protein
without the CAR binding epitope15. Alternative splicing of
transcribed CD19 messenger RNA can eliminate the domains
necessary for membrane integration or the CAR binding epitope,
again resulting in loss of surface expression or loss of regions
needed for CAR:antigen engagement16. To our knowledge,
alterations of full-length CD19 protein that lead to resistance have
not been reported.
Following translation, proteins can undergo several modiﬁcations. Among the most common post-translational modiﬁcations
of secreted and membrane proteins is the addition of glycan
residues as they transit to the cell surface. Glycosylation is an
iterative process that is regulated by glycan-modifying enzymes
found in the endoplasmic reticulum (ER) and Golgi apparatus
and serves an essential role in protein folding, stability, and
function. Signal peptide peptidase-like 3 (SPPL3) is an intramembrane aspartyl protease located in the Golgi that cleaves,
among other targets, enzymes responsible for adding glycan
residues to transiting transmembrane proteins17,18. This cleavage
results in the release of the catalytically-active ectodomain of
these glycosyltransferases, inhibiting them from adding glycans to
proteins passing through the Golgi. Thus, SPPL3 functionally
serves to restrict protein glycosylation. Antibodies and their
derivative single-chain variable fragments (scFvs) that comprise
CAR antigen-binding domains are variably sensitive to protein
glycosylation for epitope recognition19, and thus alteration of
target antigen glycosylation presents a potential mechanism of
escape from CAR T cell recognition.
We performed a genome-wide, CRISPR/Cas9-based loss-offunction screen in the human ALL cell line Nalm6 to identify
genes whose function may promote resistance to CD19-targeted
CAR T cell (CART19) cytotoxicity13. Here we show that disruption of SPPL3 caused CD19 hyperglycosylation which impairs
the binding of anti-CD19 antibodies and impairs CAR T cell
activation, thus enabling resistance to CAR therapy. We identify
that hyperglycosylation of an asparagine residue proximal to the
CAR binding epitope is directly responsible for enabling resistance. In contrast, overexpression of SPPL3 results in
2

hypoglycosylation of CD19 which is followed by protein loss,
profoundly impairing CAR T cell anti-leukemic efﬁcacy. Our
ﬁndings highlight the relevance of protein glycosylation in antigen:receptor interactions and identify post-translational modiﬁcations as essential regulators of CD19-targeted CAR T cell
efﬁcacy.
Results
Loss of SPPL3 results in resistance to CART19. We engineered
the human B-ALL cell line Nalm6 with the Brunello genomewide guide RNA library13,20 to enable the loss of function of a
single gene within each Nalm6 cell. Following engineering, cells
were combined with either control T cells or CD19-targeted CAR
T cells (CART19). Co-cultures were collected 24 h later and
underwent next-generation sequencing to identify which guide
RNAs had been enriched in the surviving CART19-exposed cells,
reﬂecting that loss of gene function promoted resistance to
CART19 killing (Fig. 1a). We previously reported that the most
enriched gene was FADD, encoding a membrane-proximal protein that initiates the apoptotic cascade upon binding of death
receptors to their ligands13. Analysis of this same dataset revealed
that the second-most enriched gene was SPPL3 (Fig. 1b),
encoding a Golgi-resident protease17,18. To validate SPPL3’s role
in resistance to CART19, we disrupted genomic SPPL3 in Nalm6
using de novo designed guide RNAs targeting either exon 4 or 6
and generated clones that had biallelic disruption (clone 1 and 2,
respectively). We conﬁrmed that these clones lacked SPPL3
protein expression and that loss of SPPL3 did not enable an
intrinsic growth advantage in Nalm6 cells (Supplementary Fig. 1a,
b). To directly assess the impact of SPPL3 loss on CART19
cytotoxic efﬁcacy, we established co-cultures of either SPPL3
wild-type (WT) or SPPL3KO Nalm6 with CART19 and monitored
Nalm6 survival over time. These studies conﬁrmed that SPPL3KO
Nalm6 were resistant to CAR T cell killing both early during coculture (48 h, Supplementary Fig. 1c) and over time (Fig. 1c). To
validate that resistance was not unique to ALL, we disrupted
SPPL3 in the CD19 + diffuse large B cell lymphoma line OCILy10. As with Nalm6, SPPL3KO OCI-Ly10 cells were also resistant to CART19 killing (Fig. 1d and Supplementary Fig. 1d),
demonstrating that loss of SPPL3 enabled resistance in two distinct histologies of CD19 + malignancy. We extended these studies to our well-established xenograft model of systemic human
ALL. NOD/SCID/γ−/− (NSG) mice were engrafted with Nalm6
cells, either wild-type or SPPL3KO, and treated with CART19 cells
6 days later. Consistent with our in vitro studies, loss of SPPL3
permitted leukemic progression in vivo (Fig. 1e and Supplementary Fig. 1e), which signiﬁcantly shortened animal survival
(Fig. 1f). Collectively, these data demonstrate that loss of SPPL3
enables robust resistance to CD19-targeted CAR therapy.
Loss of SPPL3 in ALL impairs CART19 activation. To determine if this resistance resulted from extrinsic impairments in T
cell function or intrinsic resistance to apoptosis, we combined
CART19 with either WT or SPPL3KO Nalm6 and analyzed the
expression of various surface markers of T cell activation
(Fig. 2a). As compared to cells exposed to WT Nalm6, CART19
exposed to SPPL3KO Nalm6 expressed lower levels of CD69, PD1,
and TIM3 following overnight co-culture (Fig. 2b–d). Expression
of CD107a (LAMP-1), a surrogate marker of lymphocyte degranulation, was also lower in CART19 exposed to SPPL3KO Nalm6
(Fig. 2e). We established co-cultures combining WT or SPPL3KO
Nalm6 with immortalized T cells (Jurkat) engineered to express a
CD19 CAR (Fig. 2a). These Jurkat cells were engineered with a
ﬂuorescent reporter system that transcribes GFP or eCFP upon
activation of the central T cell transcription factors NFAT or
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Fig. 1 Loss of SPPL3 results in resistance to CD19-directed CAR T cells. a Schematic of the genome-wide knockout screen in Nalm6 ALL. b Plot of
MAGeCK beta scores for genes that were enriched in CART19 targeted cells compared to untargeted T cells. c Survival of Nalm6 and d OCI-Ly10 over time
after combination with CART19 (E:T ratio 0.25:1). e Tumor radiance over time and f Survival of NSG mice treated engrafted with either WT or SPPL3KO
Nalm6 after treatment with CART19 cells (n = 7 per group) or no treatment (n = 4 per group). ***P < 0.001, **** Error bars reﬂect mean ± standard error of
the mean (s.e.m.). P < 0.0001 by two-way ANOVA with Bonferroni correction for multiple comparisons. Survival analyses were performed with the logrank test. Data were representative of n = 5 (c, d) individual experiments with distinct donor T cells. In c statistical annotations reﬂect differences between
WT and SPPL3KO clone 1 (upper) and WT and SPPL3KO clone 2 (lower). Source Data are provided as a Source Data ﬁle.

NFκB, respectively. Consistent with our ﬁndings in primary
T cells, CAR19 Jurkat cells exposed to SPPL3KO Nalm6 demonstrated less transcription factor activation (Fig. 2f, g).
While signifying a quantitative decrease in receptor-driven
stimulation, these ﬁndings did not demonstrate a complete lack of
CAR-driven activation upon exposure to SPPL3KO Nalm6, as

indicated by the increase in activation marker expression
compared to CAR-negative cells. We previously identiﬁed that
partial resistance to CAR T cell cytotoxicity enables survival of
some target cells, which leads to persistence of antigen. This
persistence drives the development of T cell dysfunction, leading
to a two-phased mechanism of therapeutic failure despite only
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Fig. 2 SPPL3KO suppresses CD19 CAR T cell activation. a Schematic of T cell activation studies. b–d, Expression of b CD69, c PD1, and d Tim3 on T cells
after overnight co-culture with WT or SPPL3KO Nalm6 cells or alone (control). e expression of CD107a on T cells after a 4-h co-culture with WT or SPPL3KO
Nalm6 cells. f, g Expression of f GFP and g eCFP, reﬂecting binding of NFAT and NFκB to their respective promoter sites in CD19 CAR-expressing Jurkat
cells. h Schematic of long-term co-culture and re-challenge study. i Survival of WT Nalm6 over time after the combination of CART19 cells previously
cultured with either WT or SPPL3KO Nalm6 cells. b–e, i Representative of n = 2 individual experiments with distinct donor T cells. f, g representative of
n = 4 individual experiments. Error bars reﬂect mean ± standard error of the mean (s.e.m.). ****P < 0.0001 by two-way ANOVA with Bonferroni correction
for multiple comparisons. Source Data are provided as a Source Data ﬁle.

partial resistance to cytotoxicity13. To evaluate if this mechanism
contributed to the resistance observed with SPPL3 loss, we
established two parallel cultures of CART19 with either WT or
SPPL3KO Nalm6 (Fig. 2h). These cultures were maintained for
4

15 days, at which time no residual WT Nalm6 remained but large
quantities of SPPL3KO Nalm6 persisted. We then isolated
CART19 cells from these cultures and re-exposed them to WT
Nalm6 to evaluate the functional capacity of these T cells.
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CART19 cells originally exposed to WT Nalm6 rapidly cleared rechallenge while CART19 cells originally exposed to SPPL3KO
Nalm6 were profoundly dysfunctional, with a complete inability
to kill WT Nalm6 upon re-challenge (Fig. 2i). We observed the
same trend when CARs contained the CD28 costimulatory
domain (Supplementary Fig. 2a), conﬁrming that this was a
costimulation-independent effect. Together, these data demonstrate that CART19 cells undergo less antigen-driven activation
by SPPL3KO Nalm6 and become progressively dysfunctional as a
result of leukemic persistence, suggesting that SPPL3KO Nalm6
resistance may result from a combination of partial evasion of T
cell killing followed by acquired T cell dysfunction.
Hyperglycosylation of CD19 leads to CAR T cell failure. While
the function of SPPL3 has not been comprehensively deﬁned, recent
studies identiﬁed one of its primary roles as a Golgi-resident intramembrane aspartyl protease is to cleave enzymes that add glycans to
extracellular asparagine residues, referred to as N-glycosylation17,18.
The extracellular domain of CD19 contains seven asparaginse residues, ﬁve of which are glycosylated under normal conditions21.
Analysis of protein lysates from both Nalm6 and OCI-Ly10 cells
revealed that CD19 had an higher apparent higher molecular weight
in the setting of SPPL3 loss (Fig. 3a and Supplementary Fig. 2b). To
determine if changes in glycosylation were responsible for this
increase in CD19 molecular weight, we treated Nalm6 lysates with
two distinct glycosylases, peptide:N-glycosidase F (PNG) or Endoglycosylase H (Endo H). These enzymes have distinct enzymatic
activity: Endo H only cleaves core (mannose) residues added in the
endoplasmic reticulum while PNG also cleaves branched glycans
added in the Golgi. This approach allowed us to simultaneously
determine if the increase in molecular weight was a result of Nglycosylation and the complexity of that glycosylation, a reﬂection of
the organellar origin. PNG treatment resulted in a signiﬁcant
reduction in CD19 size in both WT and SPPL3KO, while Endo H had
minimal impact on CD19 from either cell type (Fig. 3b), suggesting
the relative increase in molecular weight was a result of glycosylation
that occurred in the Golgi, the site of SPPL3 activity. To identify the
nature of altered CD19 glycosylation, we immunoprecipitated CD19
from WT and SPPL3KO Nalm6 and performed lectin blots. Staining
of immunoprecipitated CD19 with concanavalin A, which binds
mannose-rich glycan moieties, demonstrated no change with loss of
SPPL3. Alternatively, staining with phytohaemagglutinin-L (PHA-L),
which binds standard branched glycans, demonstrated a reduction in
binding when SPPL3 was disrupted (Supplementary Fig. 2c). In
conjunction with our glycosidase studies, this suggests that loss of
SPPL3 results in both hyperglycosylation and structural alteration of
branched glycans on CD19.
Given that antibodies and scFvs can be sensitive to glycoprotein structure, we hypothesized that hyperglycosylation may
impair the CAR binding of CD19. To evaluate this, we stained
Nalm6 cells with the same anti-CD19 antibody used to construct
our CAR antigen-binding domain (clone FMC63). Notably, this is
the same clone used to construct all FDA-approved CD19targeted CAR products. At high antibody concentrations (1:100 –
1:400 dilution) there was no difference in FMC63 binding to
CD19 on WT or SPPL3KO Nalm6 (Supplementary Fig. 3a),
however, at lower concentrations (1:800–1:3200 dilution), there
was a notable reduction in detection of CD19 on SPPL3KO Nalm6
(Fig. 3c, Supplementary Fig. 3b). We also interrogated the ability
of a distinct CD19-directed antibody (clone HIB19) to recognize
CD19 and observed less binding at all antibody concentrations on
SPPL3KO Nalm6 (Supplementary Fig. 3c), suggesting that FMC63
is not uniquely sensitive to changes in glycosylation of CD19. We
then treated WT and SPPL3KO Nalm6 with kifunensine, an
inhibitor of mannosidase I that impairs glycoprotein processing,

ARTICLE

for 10 days and repeated antibody staining. This treatment
resulted in a reduction in CD19 apparent molecular weight,
consistent with an impairment of protein glycosylation early in
the E.R. (Fig. 3d), which rescued FMC63 binding on SPPL3KO
Nalm6 cells (Supplementary Fig. 3d). We then repeated our
in vitro cytotoxicity assay and found that inhibiting glycosylation
with kifunensine also rescued CART19 efﬁcacy against SPPL3KO
Nalm6 cells, returning sensitivity to the levels seen for WT Nalm6
(Fig. 3e). These data directly implicate the altered glycan structure
of CD19 as the etiology of resistance in the setting of SPPL3 loss.
To assess the impact of altered glycosylation on a distinct
modality of CAR therapy, we turned to another B cell antigen that
is the target of CAR therapy. Similar to CD19, CD22 is broadly
expressed by B-lineage cells and is a well-described CAR target in
ALL22–24. In contrast to CD19, deletion of SPPL3 did not change
CD22 electrophoretic mobility, suggesting no change in its
glycosylation status (Fig. 3f). SPPL3KO also did not impact antiCD22 antibody binding on Nalm6 cells (Supplementary Fig. 3e).
Consistent with these observations observation, in vitro cocultures demonstrated no difference in CD22-directed CAR T cell
cytotoxicity against SPPL3KO and WT Nalm6, conﬁrming that
loss of SPPL3 did not enable resistance to CART22 (Fig. 3g and
Supplementary Fig. 3f). This observation further supports that
hyperglycosylation of CD19 is speciﬁcally responsible for
resistance to CART19.
Hyperglycosylation of CD19 N125 is responsible for failed
CART19 function. To deﬁne how increased N-glycosylation of
CD19 resulted in failed CAR T cell function, we interrogated the
role of speciﬁc CD19 asparagine residues. A previous study
identiﬁed that CD19 residues W140, R144, and P203 are essential
for FMC63 binding21. Modeling of the FMC63 binding epitope
revealed two proximal asparagine residues, one of which is normally N-glycosylated (N125) and one of which is not (N114,
Fig. 4a)21. Predicted intramolecular distance measurements reveal
that N125 is closer to the binding epitope than N114, leading us
to hypothesize that N125 is responsible for the disruption of the
FMC63 binding epitope. To evaluate this, we disrupted CD19 in
our SPPL3KO Nalm6 cells to create a dual knockout (KO) cell line
and introduced transgenic CD19 constructs in which N114 or
N125 had been mutated to glutamine, preventing glycosylation21.
These constructs were encoded on a lentiviral expression vector
that also encoded a truncated CD34 selection marker, enabling
the puriﬁcation of engineered cells independently of CD19 antibody binding. Using ﬂow cytometry-assisted cell sorting, we
produced cell lines that expressed equivalent amounts of CD19
(based on CD34 intensity) to directly evaluate how these mutations impacted anti-CD19 antibody binding capability. We found
that introduction of WT CD19 into the dual KO cells resulted in
CD19 antibody binding comparable to SPPL3KO Nalm6 (Fig. 4b),
validating the sensitivity of this system. Dual KO cells engineered
to express CD19N114Q demonstrated similar antibody binding as
SPPL3KO Nalm6 and Dual KO_CD19WT, indicating that preventing glycosylation of N114 had no impact on antibody binding. Dual KO cells engineered to express CD19N125Q, however,
demonstrated a signiﬁcant increase in FMC63 binding, comparable to WT Nalm6 (Fig. 4b), indicating that preventing hyperglycosylation at N125 enhanced FMC63 binding despite SPPL3
loss. To conﬁrm that this residue was not only responsible for
rescuing antibody binding but also sensitivity to CAR cytotoxicity, we co-cultured these cell lines with CART19 cells. Consistent
with antibody binding, dual KO_CD19N125Q cells were as sensitive to CART19 as WT Nalm6 (Fig. 4c). These data demonstrate
that loss of SPPL3 prevents CART19 activity by hyperglycosylating CD19 at N125.
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Fig. 3 Hyperglycosylation impairs detection of CD19. a Western blot of lysates from WT or SPPL3KO Nalm6 and OCI-Ly10 cells probed for CD19. Protein
electrophoresis was performed on a 6% polyacrylamide gel. Representative of n = 4 individual experiments. b Western blot of lysates from WT or SPPL3KO
Nalm6 cells that were either untreated (UT), treated with PNGase F (PNG), or treated with Endoglycosidase H (Endo H) and then probed for CD19.
Representative data of n = 3 individual experiments. Electrophoresis performed on a 6% polyacrylamide gel. c Median Fluorescence Intensity of CD19 as
detected by FMC63-APC on the surface of WT or SPPL3KO Nalm6 cells. d Western blot analysis of lysates from cells treated with kifunensine (16 ng/mL)
for 10 days and then probed for CD19. Representative of n = 2 individual experiments. e Survival of WT, untreated SPPL3KO, and kifunensine-treated
SPPL3KO Nalm6 over time in co-culture with CART19 cells (E:T ratio 0.25:1) statistical annotations reﬂect differences between SPPL3KO + kifu and WT and
SPPL3KO + kﬁu and SPPL3KO (lower). f Western blot of lysates from WT or SPPL3KO Nalm6 cells probed for CD22. Representative of n = 4 individual
experiments. g Survival of WT or SPPL3KO Nalm6 cells over time after combination with CART22 (E:T ratio 0.25:1). e, g Representative data from n = 3
individual experiments with distinct donor T cells. Error bars reﬂect mean ± standard error of the mean (s.e.m.). *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 by two-way ANOVA with Bonferroni correction for multiple comparisons. Source Data are provided as a Source Data ﬁle.

Increased SPPL3 activity results in loss of surface CD19.
Overexpression of SPPL3 has been shown to cause protein hypoglycosylation via increased glycosyltransferase cleavage17. To investigate how hypoglycosylation of CD19 impacted CART19 efﬁcacy,
we over-expressed SPPL3 in SPPL3KO Nalm6 (SPPL3KO+) using a
6

lentiviral expression vector that again contained a CD34 selection
marker. We puriﬁed CD34 + cells 5 days after engineering and
found that overexpression of SPPL3 resulted in a reduction of CD19
molecular weight (Supplementary Fig. 4a), similarly to what we
observed with kifunensine treatment, and consistent with
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Fig. 4 Hyperglycosylation of asparagine 125 is responsible for impairing CART19 efﬁcacy. a Structural modeling of the FMC63 binding epitope on CD19.
Residues in blue (R144, W140, and P203) are essential for antibody binding and proximal asparagine residues are in red (N125 and N114). b Median
Fluorescence Intensity of CD19 as detected by FMC63-APC on the surface of WT, SPPL3KO or SPPL3KO CD19KO (dual KO) Nalm6 cells engineered to
express mutated CD19 molecules. Representative data from n = 2 ﬂow cytometry experiments. c Survival of Nalm6 cells over time after combination with
CART19 (E:T ratio 0.25:1). Representative data from n = 2 experiments with independent T cell donors. Error bars reﬂect mean ± standard error of the
mean (s.e.m.). ****P < 0.0001 by two-way ANOVA with Bonferroni correction for multiple comparisons. Source Data are provided as a Source Data ﬁle.

hypoglycosylation. Evaluation of these cells over time revealed a
progressive impairment in FMC63 binding to CD19 on
SPPL3KO + cells after engineering, with the emergence of a clear
CD19-negative population that slowly increased in proportion
(Fig. 5a). Staining with the HIB19 anti-CD19 antibody clone revealed
a similar shift in binding with SPPL3 overexpression (Supplementary
Fig. 4b). We hypothesized that this loss of surface expression was due
to intracellular retention of the hypoglycosylated variant of CD19. To
evaluate this, we performed a fractionated cellular lysis to isolate
cytosolic and membrane compartments. We found that, as opposed
to lysates collected early after engineering (Supplementary Fig. 4a),
lysates collected several weeks later were devoid of CD19 in all
compartments (Fig. 5b). Quantitative reverse-transcriptase PCR
conﬁrmed that SPPL3 over-expressing cells were still transcribing the
CD19 gene (Supplementary Fig. 4c), suggesting post-transcriptional

loss of CD19. Consistent with this progressive loss, SPPL3KO +
Nalm6 became increasingly resistant to CART19. SPPL3KO +
Nalm6 combined with CART19 10 days after engineering demonstrated modest resistance (Supplementary Fig. 4d). In contrast, cocultures established 20 days after the re-introduction of SPPL3
revealed profound resistance with minimal CART19 function
(Fig. 5c). These ﬁndings indicate that hypoglycosylation of CD19
also leads to antigen escape as a result of protein loss.
Discussion
Understanding mechanisms of resistance to CAR T cells is fundamental to improving the efﬁcacy of this platform in both
hematologic and solid malignancies. Beyond enhancing therapeutic activity, identiﬁcation of tumor-intrinsic features that lead
to resistance will allow for more appropriate patient selection,
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Fig. 5 Overexpression of SPPL3 results in loss of CD19 surface expression. a Sequential ﬂow cytometric evaluation of FMC63-APC binding on
SPPL3KO + Nalm6 after overexpression of SPPL3. b Western blot of fractionated cellular lysates from WT, SPPL3KO or SPPL3KO with overexpression of
SPPL3 (SPPL3KO+) Nalm6 cells probed for CD19 performed 20 days after engineering. Representative of n = 2 individual experiments. c Survival of WT,
SPPL3KO, or SPPL3KO + Nalm6 over time when established on 20 days after re-introduction of SPPL3 (E:T 0.25:1). Representative data from n = 2
experiments with independent T cell donors. Error bars reﬂect mean ± standard error of the mean (s.e.m.). ****P < 0.0001 by two-way ANOVA with
Bonferroni correction for multiple comparisons. Statistical annotations reﬂect differences between WT and SPPL3KO (upper) or WT and SPPL3KO + Nalm6
(lower). Source Data are provided as a Source Data ﬁle.

Fig. 6 Proposed model for the mechanism of glycosylation-mediated antigen escape. (left) Normal SPPL3 function results in standard glycosylation of
CD19. (Middle) Loss of SPPL3 results in increased and altered glycosylation, disrupting the CAR binding epitope. (Right) Increased SPPL3 results initially in
decreased glycosylation followed by degradation of CD19, preventing surface presenation.

sparing patients with tumors that are unlikely to respond to
ineffective therapies. Gene and transcript-level alterations have
previously been shown to impair CAR recognition of CD19
leading to antigen escape. Here we expand the mechanisms that
lead to antigen escape to include post-translation modiﬁcations of
CD19. We found that modulation of SPPL3, either loss or overexpression, resulted in changes to CD19 glycosylation that were
both associated with impairment of anti-CD19 CAR T cell
function (Fig. 6).
A characteristic feature of malignant transformation is a global
alteration in protein glycosylation25. This has been speciﬁcally
extended to N-linked glycosylation of transmembrane proteins26.
8

As a result of this intrinsic alteration of surface protein glycosylation, some malignant cells may be predisposed to evade CAR
binding. A recent report demonstrated this phenomenon in
pancreatic cancer cells, wherein increased cellular glycosylation
occurring through an unclear mechanism was associated with
decreased CAR efﬁcacy27. Interestingly, they found that disruption of N-acetylglucosaminyltransferase V (GnTV, encoded by
MGAT5), a Golgi-resident glycosyltransferase that is a primary
target of SPPL317, improved the efﬁcacy of CAR therapy. These
studies directly complement the data presented here. The authors
of that study did not identify a mechanism by which increased
glycosylation suppressed CAR T cell efﬁcacy, or how suppressing
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glycosylation improved efﬁcacy. In our study we demonstrate that
this is a direct result of manipulating antigen glycosylation.
Together, these studies conﬁrm that glycosylation impacts the
efﬁcacy of CAR therapy in both solid and hematologic cancers.
Another study demonstrated that loss of SPPL3 impaired the
efﬁcacy of TCR-driven recognition of cancer antigens by promoting hyperglycosylation of MHC-adjacent glycosphingolipids,
thus sterically hindering MHC/TCR interactions28. While this
interaction is not relevant to MHC-independent CARs, this
observation adds further evidence that cancer cell glycosylation is
a fundamental regulator of anti-cancer cellular therapy.
Our studies focus on the manipulation of SPPL3 expression,
but these data suggest that resistance is not inherent to SPPL3
itself but to its role in regulating CD19 glycosylation. Loss of
SPPL3 does not impact the efﬁcacy of CART22, and its overexpression also enables resistance to CART19. As such, the
impact of these ﬁndings derives from the observation that CD19targeted CAR T cells are highly-sensitive to antigen glycosylation.
There are likely several other cellular pathways that can regulate
antigen glycosylation and impact tumor cell sensitivity to CAR
therapy. Given its role in cleaving glycosylation regulators,
SPPL3 serves a centralized, but indirect, role in regulating CD19
glycosylation, and thus served as an ideal system to identify this
mechanism of resistance. These studies compel correlative studies
investigating the relationship between antigen glycosylation and
the clinical efﬁcacy of antigen-targeted immunotherapies. While
evaluation of post-translational modiﬁcations is more complicated than standard protein expression studies, our data, as well
as other recently published studies, underscore the importance of
these studies using patient-derived tissues. Understanding the
burden of altered glycosylation in clinical failure will be essential
in directing the development of therapies that overcome this
mechanism of antigen escape.
Methods
All research conducted was compliant with relevant ethical research standards.
Animal studies were approved by the Washington University Institutional Animal
Care and Use Committee, Assurance #A-3381-01.

Genome-wide knockout screen. The Brunello sgRNA knockout plasmid library
was designed and produced as previously described20,29 and Nalm6 cells were
engineered as previously described13. For screening studies, 2 × 108 Brunello-edited
Nalm6 cells were combined with 5 × 107 CART19 cells or control T cells (effector:target ratio 1:4) and co-cultured in standard culture media; 5 × 107 control
Nalm6 cells were frozen for genomic DNA analysis. After 24 h, cultures were
collected, underwent dead cell removal, and were prepared for genomic DNA
extraction.

Genomic DNA extraction, guide sequencing, and analysis. Performed as
described previously13. Brieﬂy, cells from screening cultures were ﬂash-frozen as
dry pellets and resuspended in 6 mL NK lysis buffer (50 mM Tris, 50 mM EDTA,
1% SDS, pH 8) with Proteinase K followed by incubation at 55 °C overnight. The
next day, RNase A was added to the sample, mixed thoroughly, and incubated at
37 °C for 30 min. Samples were cooled and then 2 mL of pre-chilled 7.5 M
ammonium acetate was added to precipitate proteins. Samples were vortexed and
then centrifuged at ≥4000 × g for 10 min. The supernatant was then transferred to a
new 15 mL tube. About 6 mL 100% isopropanol was added to the tube, inverted 50
times, and centrifuged at ≥4000 × g for 10 min. The supernatant was discarded and
6 mL of fresh 70% ethanol was used to wash DNA, followed by centrifugation again
at ≥4000 × g for 1 min. The supernatant was discarded, and samples were left to air
dry, followed by resuspension with 500uL TE (65 °C for 1 h and at room temperature overnight). The next day, the gDNA samples were vortexed brieﬂy, and
gDNA concentration was measured. All gDNA was divided into 100 µL PCR
reactions with 5 µg of DNA per reaction. Ampliﬁcation was performed using
Takara ExTaq DNA Polymerase and the default mix protocol with the following
PCR program: (95° 2 min, (98° 10 sec, 60° 30 sec, and 72° 30 sec) × 24, 72° 5 min).
PCR products were gel puriﬁed using the QiaQuick gel extraction kit (Qiagen). The
puriﬁed, pooled library was then sequenced on a HiSeq4000 with ~5% PhiX added
to the sequencing lane. Data were analyzed using standard genome-wide library
analysis pipelines as well as customized R scripts13,30,31.
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CRISPR/Cas9-guide design, genomic engineering, and indel detection.
SPPL3 sgRNAs were designed using Benchling (http://Benchling.com). Six guide
RNAs targeting early exons were screened for knockout efﬁciency and we selected
two guides for experimental studies (targeting exon 4, sgRNA sequence: AGAC
AGATGCTCCAATTGGA; targeting exon 6, sgRNA sequence: CACCATCCATG
AGAAGCCAA). Nalm6 and OCI-Ly10 cells were electroporated using the Lonza
4D-Nucleofector Core/X Unit using the SF Cell Line 4D Nucleofector Kit (Lonza).
For Cas9 and sgRNA delivery, the ribonucleoprotein (RNP) complex was ﬁrst
formed by combining 10 µg of Cas9 Protein (Invitrogen) with 5 µg of sgRNA. Cells
were spun down at 300×g for 10 min and resuspended at a concentration of
3–5 × 106 cells/100 µL in the speciﬁed buffer. The RNP complex, 100 µL of
resuspended cells, and 4 µL of 100 µM IDT Electroporation Enhancer (IDT) were
combined and electroporated. After electroporation, cells were cultured at 37 °C for
the duration of the experimental procedures. Genomic DNA from electroporated
cells was isolated (Qiagen DNeasy Blood & Tissue Kit) and 200–300 ng were PCR
ampliﬁed using Accuprime Pfx SuperMix or Q5 Mastermix (New England Biolabs)
and 10 µM forward/reverse primers ﬂanking the region of interest. Primers were
designed such that the amplicon was at a target size ~1 kb. PCR products were gel
puriﬁed and sequenced, and trace ﬁles were analyzed to determine KO efﬁciency.
R2 values were calculated, reﬂecting the goodness of ﬁt after non-negative linear
modeling by TIDE software32.
General cell culture. Unless otherwise speciﬁed, cells were grown and cultured at a
concentration of 1 × 106 cells/mL of standard culture media (RPMI 1640 + 10%
FCS, 1% penicillin/streptomycin, 1% HEPES, 1% non-essential amino acids) at
37 °C in 5% ambient CO2. For glycosidase treatments, cultures were supplemented
with kifunensine (Santa Cruz sc-201634) at a concentration of 16 ng/mL. Jurkat,
Nalm6, and OCI-Ly10 parental cell lines were obtained from ATCC. Primary
human T cells were puriﬁed from human peripheral blood mononuclear cells,
obtained commercially from Miltenyi (Catalog #150-000-452).
Lentiviral vector production and transduction of human cells. Replicationdefective, third-generation lentiviral vectors were produced using HEK293T cells
(ATCC ACS-4500). Approximately 10 × 106 cells were plated in T175 culture
vessels in DMEM + 10% FCS culture media and incubated overnight at 37 °C.
Eighteen to twenty-four hours later, cells were transfected using a combination of
Lipofectamine 2000 (96 μL, Invitrogen), pMDG.1 (7 μg), pRSV.rev (18 μg),
pMDLg/p.RRE (18 μg) packaging plasmids and 15 μg of expression plasmid.
Lipofectamine and plasmid DNA was diluted in 4 mL Opti-MEM media prior to
transfer into lentiviral production ﬂasks. At both 24 and 48 h following transfection, culture media was isolated and concentrated using high-speed ultracentrifugation (8500×g overnight). For T cell engineering, CD4 and CD8 T cells
were isolated from Miltenyi PBMC packs and combined at a 1:1 ratio, activated
using CD3/CD28 stimulatory beads (Thermo Fisher) at a ratio of 3 beads/cell, and
incubated at 37 °C overnight. The following day, CAR lentiviral vectors were added
to stimulatory cultures at an MOI of 3. Beads were removed on day 6 of stimulation, and cells were counted daily until growth kinetics and cell size demonstrated
they had rested from stimulation. For cancer cell engineering, vectors were combined with cells at an MOI of 2.
Co-culture assays. For cytotoxicity assays, CAR T cells were combined with target
cells at various E:T ratios and co-cultures were evaluated for an absolute count of
target cells by ﬂow cytometry. All co-cultures were established in technical triplicate. Cultures were maintained at a concentration of 1e6 total cells/mL. For reexposure assays, CAR + T cells were sorted by ﬂuorescence-assisted cell sorting
using a truncated CD34 selection marker encoded in the CAR plasmid backbone.
T cells were then recombined with target leukemia cells at an effector:target ratio of
1:4 and killing was measured as described. For activation marker studies, CAR or
Jurkat T cells and Nalm6 cells were combined at an E:T ratio of 1:4 and evaluated
by ﬂow cytometry the following day. Jurkat cells were engineered to express a dual
ﬂuorescence reporter system indicating activation of transcription factor activity as
previously described33. For degranulation assays (CD107a assessment), T cells were
combined with Nalm6 as described and combined with an antibody cocktail of
CD107a-PECy7 (clone H4A3, Biolegend 328607, diluted 1:100) and stimulatory
antibodies against CD28 (eBiosciences 16-0288-81, diluted 1:50) for 1 h. Intracellular protein transport was halted by the addition of GolgiStop (BD Biosciences
554724) and cells were incubated for an additional 3 h. Cells were then harvested
and stained for CD34 (BD 555824, diluted 1:50) and analyzed by ﬂow cytometry.
Xenograft mouse models. About 6–10-week-old female NOD-SCID-γc−/−
(NSG) mice were obtained from the Jackson Laboratory and maintained in
pathogen-free conditions with standard dark/light cycles and ambient temperature
and humidity. Each experimental group contained between 4–7 mice. Animals
were injected via tail vein with 1 × 106 WT or SPPL3KO Nalm6 cells in 0.2 mL
sterile PBS. On day 6 after tumor delivery, 1 × 106 T cells were injected via tail vein
in 0.2 mL sterile PBS. Animals were monitored for signs of disease progression and
overt toxicity, such as xenogeneic graft-versus-host disease, as evidenced by >10%
loss in body weight, loss of fur, diarrhea, conjunctivitis and disease-related hind
limb paralysis. Disease burdens were monitored over time using the Spectral
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Instruments AMI bioluminescent imaging system. Animal were sacriﬁced when
tumor burden reached >1 × 1010 photons/sec/steradian/cm2. No animal exceeded
this burden. Animal studies were approved by the Washington University Institutional Animal Care and Use Committee, Assurance #A-3381-01.
Flow cytometry. Cells were resuspended in FACS staining buffer (PBS + 3% fetal
bovine serum) using the following antibodies: CD3 (clone OKT3, BD Biosciences
555342, diluted 1:50), PD1 (clone EH12.2H7, BioLegend, 329928, diluted 1:80),
Tim3 (clone 7D3, BD Biosciences 565566, diluted 1:100), CD22 (clone HIB22, BD
Biosciences 562860, diluted 1:100), CD19 (clone FMC63, Novus Biologicals 52716,
diluted 1:80-1:32000; clone HIB19, BD Biosciences 555413, diluted 1:50), CD107aPECy7 (clone H4A3, Biolegend 328607, diluted 1:100), CD34 APC (BD 555824,
diluted 1:50). CARs transduction was evaluated by staining for a truncated
CD34 selection marker located downstream of a P2A ribosomal skip sequence
from the CAR transgene. Data were acquired on an Attune NxT cytometer
(Thermo). All data analysis was performed using FlowJo 9.0 software (FlowJo,
LLC). The gating strategy can be found in Supplementary Fig. 5.
Western blotting. Nalm6 and OCI-Ly10 cells were counted and 5 × 106 cells were
washed in cold PBS. Cell pellets were resuspended in RIPA lysis buffer supplemented with phosphatase and protease inhibitors and incubated on ice for 15 min,
followed by centrifugation at 14,000 × g for 15 min. Lysate concentration was
quantiﬁed using the Pierce BSA Protein Assay Kit (Thermo), combined with 4x
LDS buffer, denatured at 100 °C for 10 min, and then reduced to a ﬁnal concentration of 20% beta-mercaptoethanol. 10–20 ug of protein was loaded into each
well of a Bis-Tris gel (either 4–12% gradient, 6%, or 15%) and proteins were
separated using standard electrophoresis followed by transfer to nitrocellulose
membranes. Proteins were labeled with SPPL3 (EMD Millipore #MABS1910),
CD19 (#3574), CD22 (#67434), Actin (#4970) or GAPDH (#2118, all from Cell
Signaling, all diluted 1:1000), followed by secondary antibody staining using either
anti-rabbit (Cell Signaling #7074, diluted 1:5000), or anti-mouse (Cell Signaling
#7076, diluted 1:5000) HRP-linked antibodies followed by visualization. Cell
components were isolated using the Cell Signaling Cell Fractionation Kit (#9308).
Unprocessed plots can be found in Source Data Files.

Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Guide library sequencing data were available from Gene Expression Omnibus (GEO)
using the accession number GSE130663. Sequences used for predictive modeling and
analysis were derived from the Protein Database entry 6AL5. The remaining data are
available with the Article, Supplementary Information, or Source Data File. Source data
are provided with this paper.
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